Authors

Latest:

Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers

The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.

Efrat Luttwak, MD, MPH

Latest:

Bispecific Antibodies May Revolutionize the Management of B-Cell Lymphoma

The safety profiles and the high response rates observed with bispecific antibodies in patients with B-cell lymphoma suggest that these agents possess the potential to revolutionize the management of these diseases, particularly follicular lymphoma.

Ralph Boccia, MD, Johns Hopkins Medicine

Latest:

Risk Stratification of Myelodysplastic Syndromes [MDS]

Ralph Boccia, MD, FACP, and Hetty Carraway, MD, review Myelodysplastic Syndromes [MDS] risk stratification criteria used in their practices.

Libusha Kelly, PhD

Latest:

The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality

One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.

Afaf E. Osman, MD

Latest:

Dr. Osman on the SELECT-MDS Trial in Higher-Risk Myelodysplastic Syndrome

Afaf E. Osman, MD, discusses the phase 3 SELECT-MDS trial in patients with higher-risk myelodysplastic syndrome.

Martin Edelman, MD

Latest:

Drs Edelman and Fleisher on Personalizing and Adapting Treatment Approaches in Clinical Trials

Martin Edelman, MD, and Linda Fleisher, PhD, MPH, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

Gunsagar Gulati, MD,

Latest:

Dr. Gulati on the Prevalence of TSC1 and TSC2 Mutations in Solid Tumors

Gunsagar Gulati, MD, discusses the prevalence of TSC1 and TSC2 mutations in solid tumors.

Howard D. Edington, MD

Latest:

Dr. Edington on the Utilization of TVEC Therapy in Melanoma

Howard D. Edington, MD, discusses the use of talimogene laherparepvec in melanoma.

Arpita Gandhi, MD, MS

Latest:

OncLive Peer Exchange on Allo-HSCT: Conclusion of Discussion

The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.

YunZu Michele Wang, MD

Latest:

Dr. Wang on the Potential Utility of Ruxolitinib in Pediatric Patients With cGVHD

YunZu Michele Wang, MD, discusses the potential utility of ruxolitinib in children and young adult patients with chronic graft-versus-host disease.

Marisol Miranda-Galvis, DDS, MS, PhD

Latest:

Dr Miranda-Galvis on the Investigation of Social Determinants of Health in Hematologic Malignancies

Marisol Miranda-Galvis, DDS, MS, PhD, discusses the investigation of disparities in survival outcomes of patients with hematologic malignancies relating to social determinants.

Steven Scott West

Latest:

The Investigational Pipeline for Advanced BTC

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss ongoing research efforts in advanced biliary tract cancer.

Daniel Olson, MD

Latest:

Dr Olson on the Potential Benefit of Lifileucel in Relapsed/Refractory Metastatic Melanoma

Daniel Olson, MD, discusses the benefit associated with lifileucel in patients with unresectable or metastatic melanoma.

Jill Alldredge, MD

Latest:

Dr. Alldredge on Managing AEs With PARP Inhibitors in Ovarian Cancer

Jill Alldredge, MD, discusses the toxicities associated with PARP inhibition and the management of those adverse effects in patients with ovarian cancer.

Amy DeZern, MD, MHS, Sidney Kimmel Comprehensive Cancer Center

Latest:

Treatment Options in Myelodysplastic Syndromes

Javier Torres-Roca, MD

Latest:

Dr. Torres-Roca on Optimizing Radiation Therapy With GARD-Based Dosing in Oncology

Javier Torres-Roca, MD, discusses optimizing radiation therapy with genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Ami Umesh Badami, MD

Latest:

Dr Badami on the Optimal Selection of Second-Line TKIs in ccRCC

Ami Umesh Badami, MD, discusses clinical research that has informed treatment selection in the second-line clear cell renal cell carcinoma setting.

Harry Gill, MD, FRCP, FRCPath

Latest:

Dr Gill on the Efficacy and Genomic Features of Ropeginterferon Alfa-2B in Myelofibrosis

Harry Gill, MD, FRCP, FRCPath, discusses updated efficacy data and analysis of genomic characteristics for ropeginterferon alfa-2B in primary myelofibrosis.

Nikita Sinha, MD

Latest:

Dr. Sinha on the Antitumor Effects of Onvansertib in a Preclinical Endometroid Endometrial Cancer Model

Nikita Sinha, MD, discusses the potential effects of onvansertib on endometroid endometrial cancer pathogenesis in a preclinical model.

Craig Eckfeldt, MD, PhD

Latest:

Dr Eckfeldt on the Treatment Paradigm and Current Challenges in MDS

Craig Eckfeldt, MD, PhD, discusses the current treatment paradigm in MDS and the unmet needs in different subsets of patients.